ADT
69
3
GD
69
3
FSLR
64
7
NKE
50
5
MKC
48
7
CSX
44
-6
STZ
52
4
HSIC
57
15
CHD
39
2
BLK
73
7
DVN
57
7
KEY
55
8
QRVO
53
9
PSX
67
8
AMP
69
6
SIG
55
8
OKE
45
3
COP
51
3
CAH
50
-3
SRE
68
7
ADT
69
3
GD
69
3
FSLR
64
7
NKE
50
5
MKC
48
7
CSX
44
-6
STZ
52
4
HSIC
57
15
CHD
39
2
BLK
73
7
DVN
57
7
KEY
55
8
QRVO
53
9
PSX
67
8
AMP
69
6
SIG
55
8
OKE
45
3
COP
51
3
CAH
50
-3
SRE
68
7
Financhill
Back

Acadia Pharmaceuticals 10K Form

Buy
53

ACAD
Acadia Pharmaceuticals

Last Price:
$25.76
Seasonality Move:
-0.83%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-09 10Q ACAD/Acadia Pharmaceuticals Quarterly
2024-02-28 10K ACAD/Acadia Pharmaceuticals Annual
2023-11-03 10Q ACAD/Acadia Pharmaceuticals Quarterly
2023-08-03 10Q ACAD/Acadia Pharmaceuticals Quarterly
2023-05-08 10Q ACAD/Acadia Pharmaceuticals Quarterly
2023-02-28 10K ACAD/Acadia Pharmaceuticals Annual

Receive ACAD News And Ratings

See the #1 stock for the next 7 days that we like better than ACAD

ACAD Financial Statistics

Sales & Book Value

Annual Sales: $957.8M
Cash Flow: $63.7M
Price / Cash Flow: 48.8
Annual Sales: $4.88
Price / Book: 5.28

Profitability

EPS (TTM): 1.33000
Net Income (TTM): $222.2M
Gross Margin: $861M
Return on Equity: 32.53%
Return on Assets: 20.43%

Acadia Pharmaceuticals Earnings Forecast

Key Acadia Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 20 years for ACAD is 89.89%.
  • The Selling, General & Administrative Expenses for ACAD have been equal to 0.00% of Gross Profit Margin.
  • The Research & Development expenses have been 31.66% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of ACAD is 23.64% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 12 years.

Acadia Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ACAD
CUSIP: 004225
Website: acadia.com

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 2.91
Quick Ratio: 2.63

Price-to-Earnings

Trailing P/E Ratio: 18.93
Forward P/E Ratio: 30.08

ACAD Technical Analysis vs Fundamental Analysis

Buy
53
Acadia Pharmaceuticals (ACAD) is a Buy

Is Acadia Pharmaceuticals a Buy or a Sell?